In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Rigel Pharmaceuticals (NASDAQ: RIGL) was $38.94 for the day, down -2.82% from the previous closing price of $40.07. In other words, the price has decreased by -$2.82 from its previous closing price. On the day, 0.68 million shares were traded. RIGL stock price reached its highest trading level at $40.94 during the session, while it also had its lowest trading level at $38.53.
Ratios:
Our analysis of RIGL’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.44 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.62. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 2.02. In the meantime, Its Debt-to-Equity ratio is 0.75 whereas as Long-Term Debt/Eq ratio is at 0.47.
Piper Sandler Downgraded its Overweight to Neutral on June 08, 2022, whereas the target price for the stock was revised from $7 to $1.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 04 ’25 when Schorno Dean L sold 2,036 shares for $20.92 per share. The transaction valued at 42,595 led to the insider holds 58,969 shares of the business.
Schorno Dean L sold 1,734 shares of RIGL for $38,020 on Feb 05 ’25. The EVP & Chief Financial Officer now owns 57,235 shares after completing the transaction at $21.93 per share. On Feb 04 ’25, another insider, Santos David A, who serves as the EVP, Chief Commercial Officer of the company, sold 2,125 shares for $20.92 each. As a result, the insider received 44,457 and left with 53,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RIGL now has a Market Capitalization of 698478464 and an Enterprise Value of 671414208. As of this moment, Rigel’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.19, and their Forward P/E ratio for the next fiscal year is 10.75. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.61 while its Price-to-Book (P/B) ratio in mrq is 8.52. Its current Enterprise Value per Revenue stands at 2.506 whereas that against EBITDA is 6.274.
Stock Price History:
The Beta on a monthly basis for RIGL is 1.26, which has changed by 2.1102235 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, RIGL has reached a high of $41.25, while it has fallen to a 52-week low of $11.95. The 50-Day Moving Average of the stock is 69.48%, while the 200-Day Moving Average is calculated to be 87.59%.
Shares Statistics:
RIGL traded an average of 357.20K shares per day over the past three months and 1128850 shares per day over the past ten days. A total of 17.94M shares are outstanding, with a floating share count of 17.44M. Insiders hold about 2.79% of the company’s shares, while institutions hold 77.70% stake in the company. Shares short for RIGL as of 1753920000 were 2511219 with a Short Ratio of 7.03, compared to 1751241600 on 2172820. Therefore, it implies a Short% of Shares Outstanding of 2511219 and a Short% of Float of 14.38.
Earnings Estimates
A detailed examination of Rigel Pharmaceuticals (RIGL) is currently in progress, with 6.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.67, with high estimates of $1.03 and low estimates of $0.16.
Analysts are recommending an EPS of between $6.02 and $0.93 for the fiscal current year, implying an average EPS of $4.91. EPS for the following year is $3.31, with 6.0 analysts recommending between $5.78 and $1.1.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $65.6M to a low estimate of $59.1M. As of the current estimate, Rigel Pharmaceuticals’s year-ago sales were $55.31MFor the next quarter, 5 analysts are estimating revenue of $64.77M. There is a high estimate of $69.7M for the next quarter, whereas the lowest estimate is $60.9M.
A total of 5 analysts have provided revenue estimates for RIGL’s current fiscal year. The highest revenue estimate was $290.32M, while the lowest revenue estimate was $275M, resulting in an average revenue estimate of $281.09M. In the same quarter a year ago, actual revenue was $179.28MBased on 6 analysts’ estimates, the company’s revenue will be $270.23M in the next fiscal year. The high estimate is $346.4M and the low estimate is $232.65M.
